Tag: US Market

As of fiscal 2021, ADP has successfully migrated most of its small and midsize clients to its strategic platforms and will be migrating enterprise clients to its new HCM platform over the coming decade, as well rolling out its new underlying payroll and tax engines. While we expect platform migrations to ultimately result in higher retention and profitability, the forced migrations will likely create a catalyst for enterprise clients to reassess providers, temporarily hindering both metrics.

ADP faces fierce competitive pressure from nimble upstarts, legacy peers, accounting software and ERP providers. We expect new solutions will allow ADP to compete more aggressively on functionality, reduce software maintenance costs and provide scope for greater operating leverage, supporting margin uplift. However, we anticipate increasing competitive pressure will result in greater pricing pressure and force ADP to sustain high levels of investment to ensure the functionality of its product offering remains competitive. This investment is in addition to the continued investment in sales and implementation required to roll out new solutions and migrate clients. As such, we expect ADP’s price increases will be limited to about 0.5% a year, in line with recent growth but below long-term averages, limiting margin expansion to about two percentage points over the next five years.

We expect increased regulatory complexity, tight labor markets and growing adoption of hybrid work will underpin strong demand for ADP’s solutions supporting greater share of wallet and modest market share gains in the small and midsize market. This includes greater penetration of the outsourced payroll and HR model. However, we expect forced platform migrations to hamper ADP’s enterprise market share over the next decade before gradually recovering as the new platform is adopted in the market. In aggregate, we expect ADP’s overall market share to remain broadly flat for the five years to fiscal 2026 before gradual growth as platform migrations complete.

Financial Strength

ADP is in a strong financial position. At the end of fiscal 2021, ADP’s balance sheet was modestly geared with net debt/EBITDA of 0.1. During fiscal 2021, ADP almost tripled long-term debt to USD 3 billion to fund share repurchases and optimise its capital structure with low cost debt. We expect ADP’s annual operating income can comfortably cover annual interest expense on its debt at least 60 times over our forecast period. ADP also has access to short term funding facilities to meet client’s obligations rather than liquidating available for sale securities. ADP has returned over USD 18 billion of capital to shareholders during the eight years to fiscal 2021 through dividends and share repurchases. We expect ADP’s strong free cash flow generation will support a dividend payout ratio of about 60% over our forecast period. The balance sheet is robust, and ADP has ample scope to increase leverage to execute on bolt on acquisitions. 

Bulls Say 

• ADP benefits from high client switching costs, a scale based cost advantage, intangible brand assets and a powerful referral network.
• Despite facing fierce competitive pressures and undergoing forced platform migrations, ADP has retained high revenue retention and improved operating margins over the past decade.
• ADP has a strong track record of returning capital to shareholders through dividends and share repurchases.

Company Profile

Automatic Data Processing, or ADP, is a provider of payroll and human capital management, or HCM, solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 920,000 clients primarily in the United States. ADP’s employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.

 (Source: Morningstar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Advisors on LPL’s platform serve approximately 4% of wealth management assets in the United States. Through its ClientWorks portal, the company offers a one-stop solution for advisors that incorporates billing, account analytics, research, trading, and relationship-management tools. LPL aims to offer services to all advisors regardless of business model.

Production retention, which measures the percentage of advisor-generated revenue maintained from the previous year, has recently been over 95%. Recently, LPL has been making moves to improve its value proposition to advisors, with the rollout of a new online portal and the purchase, and subsequent integration, of Advisory World. Acquisitions of advisor networks have also been a source of growth, with the 2017 acquisition of NPH for $325 million and the wealth management business of Waddell & Reed in 2021 for $300 million showing that LPL is willing and able to buy growth outright when it makes sense to do so. 

Financial Strength

LPL’s financial strength is adequate. At the end of 2020, the company had $2.3 billion of long-term debt. With a debt/equity ratio of about 1.8 times, the company is fairly leveraged. The company also has about $1.9 billion of goodwill and intangibles on its balance sheet, so has no tangible equity. The bulk of its debt, about $1.4 billion, will come due in 2024, with the rest due the following year. With a debt/adjusted EBITDA ratio of around 2.5 times, LPL should have sufficient cash to meet these financial obligations.LPL has paid a consistent $0.25 quarterly dividend since first-quarter 2015. 

Our fair value estimate correlates to a price/forward earnings multiple of 22 times and an enterprise value/EBITDA multiple of 12.5 times. Positive adjustments to our fair value estimate include $6.50 from earnings since our previous valuation update, $20.50 from recent growth in client assets and higher projected growth in client assets, $10.50 from increasing the growth rate and assumed returns on capital after year 10 in our model, and $3.50 of miscellaneous adjustments.

Bulls Say’s

• LPL has been able to weather the storm of a changing industry, and expanding margins suggest that its business model remains intact.
• The company has been moving toward more recurring revenue, such as advisory fees and revenue from client cash balances, which the market may reward.
• LPL has the resources to recruit aggressively, and improvements in feedback receptiveness should help it maintain strong retention rates.

Company Profile 

LPL Financial Holdings is an independent broker/dealer that provides a platform of proprietary technology, brokerage, and investment advisory services to financial advisors and institutions. The company also provides financial advisors licensed with insurance companies customized clearing services, advisory platforms, and technology solutions. LPL provides a range of services through its subsidiaries. Private Trust supplies trust administration, investment management oversight, and custodial services for estates and families; Independent Advisers Group offers investment advisory solutions to insurance companies; and LPL Insurance Associates operates as a brokerage general agency that offers life, long-term care, and disability insurance sales and services.

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Powered by store openings and retail expansion in the 2010-15 period, Michael Kors became one of the largest American handbag producers in sales and units. However, over the past five years, growth has stalled due to markdowns of bags at third-party retail and declining sales at company-owned stores. While Capri has reduced distribution to limit discounting of Michael Kors bags, competition in the American handbag market is fierce and growth is limited. Moreover, the company is in the process of closing more than 100 Michael Kors stores.

Capri spent a steep $3.4 billion to purchase Jimmy Choo and Versace to boost its status as a luxury house and reduce its dependence on Michael Kors. However, we do not think these deals have changed Capri’s no-moat status as the acquired brands have more fashion risk, less profitability, and narrower appeal than Michael Kors. Capri is investing in store remodels, store openings, and expanding the set of accessories for both Jimmy Choo and Versace, but we don’t think these efforts will yield the intended gains, particularly given the severe interruption we expect from COVID-19. 

We believe Michael Kors lacks the brand strength (and ultimately pricing power) to provide an economic moat for Capri, rating poorly on the criteria that Morningstar uses to evaluate luxury brands, in contrast to others such as narrow-moat Tapestry’s Coach.

Financial Strength

Capri has debt, but it is very manageable. At the end of June 2021, it had total shortand long-term debt of $1.3 billion, but it also had more than $350 million in cash. Capri, though, has $1.3 billion in available borrowing capacity it amended its revolving and term loan credit agreement.Thus, Capri has no significant debt maturities prior to 2023. Capri has also recently modified its debt covenants, allowing a maximum leverage ratio of 3.75 times. Its debt/adjusted EBITDA was 2.3 times at the end of fiscal 2021, and we forecast this will decline to 1.2 times at the end of fiscal 2022. The firm averaged more than $500 million in annual buybacks in fiscal 2015-20. We now forecast its share repurchases at an annual average of about $630 million over the next decade. However, Capri does not pay dividends. We forecast its fiscal 2021 capital expenditures will rise to $205 million (3.9% of sales) from just $111 million (2.7% of sales) last year. Long term, we forecast Capri’s annual capital expenditures as a percentage of sales at 4.3% as management works to improve the performance at Jimmy Choo and Versace.

Bulls Say

• Michael Kors is one of the largest brands in terms of units and sales in the high-margin handbag market, and we think this positioning should aid its prospects as it looks to grow in complementary categories like footwear.
• Michael Kors has reduced its dependence on wholesale customers, which we view favorably as increased direct-to-consumer sales allow for better pricing and control over marketing.
• The acquisitions of Jimmy Choo and Versace afford diversification opportunities by bringing two luxury brands that maintain products with high price points into the fold.

Company Profile

Michael Kors, Versace, and Jimmy Choo are the brands that comprise Capri Holdings. Capri markets, distributes, and retails upscale accessories and apparel. Michael Kors, Capri’s largest and original brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, third-party retailers, and e-commerce. Milan-based Versace (acquired in 2018) is known for its ready-to-wear luxury fashion. Jimmy Choo (acquired in 2017) is best known for women’s luxury footwear. John Idol has served as CEO since he was part of a group that acquired Michael Kors in 2003.

 (Source: Morningstar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

The emerging biotech’s first commercial vaccine, for COVID-19, received its first authorization in December 2020, and its early-stage pipeline and mRNA technology platforms have caught the eye of several large pharmaceutical companies, resulting in collaborations and partnerships.

Further, the company has a burgeoning vaccine pipeline for infectious diseases. In partnership with the Bill & Melinda Gates Foundation, BioNTech is developing vaccines for HIV and tuberculosis, and the company’s COVID-19 program in partnership with Pfizer and Fosun Pharma was built off an existing partnership with Pfizer for an influenza vaccine. The COVID-19 vaccine, Comirnaty (BNT162b2), quickly progressed through human trials, culminating in authorization in the United States and Europe in December 2020. 

Company’s Future Outlook

We think the vaccine’s excellent efficacy, strong supply, and early leadership on the market all support $35 billion in Comirnaty sales in 2021 and $43 billion in 2022 (BioNTech books half of Pfizer’s gross profits, profit share from other smaller partners, and direct sales in Germany and Turkey). However, the long-term market for coronavirus vaccines is uncertain, and even if there is demand for continued vaccination in the long run, we expect the market to be competitive.

BioNTech’s COVID-19 Vaccine Success Could Help It Build a Moat on mRNA Technology

We believe BioNTech has a positive moat trend due to strengthening intangible assets in its pipeline. Over the next five years, we expect several data readouts, assets progressing through trials, and even the company’s first potential approval. Further, testing new combinations of treatments, which tends to improve efficacy in cancer treatment, will also strengthen the competitive position of BioNTech’s platforms. 

The positive results and subsequent authorization of BNT162b2, BioNTech’s vaccine against SARS-CoV-2, support our positive moat trend rating. While the long-term profit outlook for BNT162b2 remains uncertain, we believe its success demonstrates the potential of the company’s mRNA vaccine platform.

Financial Strength 

BioNTech has historically burned through cash to fund research and development of its pipeline. The company has minimal debt on its balance sheet, as it has funded discovery and development with equity issues,collaboration payments from partnerships with large pharmaceutical firms as well as a large inflow of cash from Comirnaty gross profits in 2021 and 2022 and believe this will continue for long term basis.Outside of BioNTech’s COVID-19 vaccine candidates, we think the earliest approval could arrive in 2023, which would put the company on a path toward steady profitability. Management has taken advantage of a couple of opportunities to acquire early-stage assets and expand its geographic footprint to establish a U.S. research hub at low prices. We expect the near-term focus for capital allocation to remain on its pipeline of vaccines and other therapies.

Bull Says

• BioNTech’s pipeline, which relies on expertise in mRNA and bioinformatics, will be difficult to replicate by competitors. 
• BioNTech will be able to command a premium price with its personalized cancer therapies, if successful. 
• The rapid development of COVID-19 vaccine Comirnaty bodes well for the rest of BioNTech’s pipeline and the future of its mRNA research platform.

Company Profile

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company’s oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.

 (Source: Morningstar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.